Stocktoria
AGIOS PHARMACEUTICALS, INC. AGIO
AGIOS PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | $0 | $0 | $117.9M | $94.4M | $43.0M | $69.9M |
| R&D expense | $339.5M | $301.3M | $295.5M | $279.9M | $257.0M | $220.8M | $214.3M | $341.3M | $292.7M | $220.2M |
| SG&A expense | $180.3M | $156.8M | $119.9M | $121.7M | $121.4M | $115.1M | $102.0M | $114.1M | $71.1M | $50.7M |
| Operating income | -$472.1M | -$425.7M | -$391.5M | -$389.0M | -$378.4M | -$335.9M | -$316.3M | -$362.5M | -$320.8M | -$201.0M |
| Income tax | -$1.0M | $44.2M | $0 | $0 | — | — | $0 | $0 | $0 | $0 |
| Net income | -$412.8M | $673.7M | -$352.1M | -$231.8M | $1.6B | -$327.4M | -$411.5M | -$346.0M | -$314.7M | -$198.5M |
| EPS (diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | — | — | — |
| Operating cash flow | -$373.0M | -$389.8M | -$296.1M | -$309.5M | -$407.3M | -$290.8M | -$370.6M | -$304.4M | -$285.2M | $38.6M |
| Free cash flow | -$377.3M | -$391.5M | -$297.1M | -$314.4M | -$413.1M | -$304.9M | -$382.6M | -$311.4M | -$289.9M | $28.6M |
| Cash & equivalents | $89.1M | $76.2M | $88.2M | $139.3M | $203.1M | $127.4M | $80.9M | $70.5M | $102.7M | $160.8M |
| Inventory | $32.9M | $27.6M | $19.1M | $8.5M | $0 | $14.7M | $7.3M | $869,000 | $0 | — |
| Total assets | $1.3B | $1.7B | $937.1M | $1.2B | $1.4B | $853.0M | $890.7M | $858.5M | $614.4M | $619.1M |
| Total liabilities | $104.1M | $122.2M | $126.1M | $137.9M | $145.8M | $453.5M | $250.2M | $170.9M | $238.9M | $260.5M |
| Shareholders' equity | $1.2B | $1.5B | $811.0M | $1.1B | $1.3B | $399.5M | $640.5M | $687.5M | $375.5M | $358.6M |
Growth · year-over-year · Revenue CAGR -2.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +48.0% | +36.1% | +88.4% | — | — | -100.0% | +24.9% | +119.4% | -38.5% | +18.2% |
| Net income growth | -161.3% | — | — | -114.4% | — | — | — | — | — | — |
| EPS growth | -161.2% | — | — | -115.9% | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | — | — | — | — | — | -1111.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.